Formycon AG (ETR:FYB)
18.90
+0.06 (0.32%)
Oct 26, 2026, 5:35 PM CET
Formycon AG Revenue
Formycon AG had revenue of 12.66M EUR in the quarter ending June 30, 2026, with 242.52% growth. This brings the company's total for the last twelve months to 61.24M, up 18.28% year-over-year. In the year 2025, Formycon AG had annual revenue of 44.48M, down -36.17%. That makes Formycon AG the 25,577th largest company in the world by revenue and 395th in Germany.
Revenue (ttm)
61.24M
Revenue Growth
+18.28%
P/S Ratio
5.44
Revenue / Employee
312.46K
Employees
196
Market Cap
334.02M
Revenue by Geography
- Rest of The World 19.97M 44.9%
- Switzerland 13.42M 30.2%
- Germany 11.09M 24.9%
Fiscal year ended Dec 31, 2025 See the full Formycon AG breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 44.48M | -25.20M | -36.17% |
| Dec 31, 2024 | 69.67M | -8.02M | -10.32% |
| Dec 31, 2023 | 77.70M | 35.20M | 82.83% |
| Dec 31, 2022 | 42.50M | 5.88M | 16.07% |
| Dec 31, 2021 | 36.61M | 2.32M | 6.76% |
| Dec 31, 2020 | 34.30M | 1.14M | 3.43% |
| Dec 31, 2019 | 33.16M | -42.96B | -99.92% |
| Dec 31, 2018 | 42.99B | 42.96B | 148,135.43% |
| Dec 31, 2017 | 29.00M | 9.47M | 48.48% |
| Dec 31, 2016 | 19.53M | 2.61M | 15.41% |
| Dec 31, 2015 | 16.92M | 4.34M | 34.49% |
| Dec 31, 2014 | 12.59M | 12.31M | 4,456.93% |
| Dec 31, 2013 | 276.17K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bayer Aktiengesellschaft | 45.38B |
| Fresenius SE & Co. KGaA | 23.28B |
| Siemens Healthineers AG | 23.17B |
| Merck KGaA | 21.14B |
| Medios AG | 2.16B |
| MEDICLIN Aktiengesellschaft | 819.84M |
| Evotec SE | 717.28M |
| Eckert & Ziegler SE | 312.50M |
Formycon AG News
- 3 days ago - EQS-AFR: Formycon AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements - Wallstreet:Online
- 5 days ago - EQS-News: Formycon and Biocelys Combine Complementary Development and Manufacturing Expertise in New Biosimilar Project FYB286 - Wallstreet:Online
- 6 days ago - EQS-RPT: Formycon AG: Release according to Article 111c of the AktG [the German Stock Corporation Act] with the objective of Europe-wide distribution - Wallstreet:Online
- 13 days ago - USFDA accepts biosimilar application of Zydus and German firm for Keytruda - The Times of India
- 13 days ago - FDA Accepts BLA For Formycon And Zydus' Keytruda Biosimilar FYB206 ;Shares Rise - Nasdaq
- 13 days ago - EQS-News: Formycon and Zydus: FYB206 Becomes First Publicly Announced Keytruda Biosimilar Accepted for Review by FDA - Wallstreet:Online
- 20 days ago - EQS-News: Formycon Optimizes Biosimilar Development with AI-Powered Technologies: Digital Solutions Enhance Development Efficiency as Part of the FYB4GROWTH Strategy - Wallstreet:Online
- 4 weeks ago - EQS-News: Formycon sets Benchmark in Biosimilar Development: Scientific Foundation of the innovative Development Program for FYB206 published in the Journal BioDrugs - Wallstreet:Online